These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial. McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013 [TBL] [Abstract][Full Text] [Related]
3. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin. Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794 [TBL] [Abstract][Full Text] [Related]
4. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2004)]. Goto H; Takeda H; Kawai S; Watanabe T; Okazaki M; Shimada K; Nakano K; Yokouchi H; Ikemoto H; Mori T; Igari J; Oguri T; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Kudo K; Kobayashi N; Tanaka T; Sumitomo M; Matsushima T; Oka M; Niki Y; Suga M; Tosaka M; Kohno S; Hirakata Y; Kondou A; Matsuda J; Nakano M; Nasu M; Hiramatsu K; Oikawa S Jpn J Antibiot; 2006 Oct; 59(5):323-54. PubMed ID: 17180803 [TBL] [Abstract][Full Text] [Related]
5. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2005)]. Goto H; Takeda H; Kawai S; Watanabe S; Okazaki M; Shimada K; Nakano K; Yokouchi H; Mori T; Igari J; Oguri T; Yamamoto M; Kudo K; Kobayashi N; Tanaka T; Yoshimura K; Kawabata M; Nakamori Y; Sumitomo M; Inoue H; Nakadate T; Suwabe A; Ashino Y; Aoki N; Honma Y; Suzuki Y; Karasawa Y; Oka M; Kobashi Y; Kohno S; Hirakata Y; Kondou A; Matsuda J; Nakano M; Oikawa S Jpn J Antibiot; 2008 Aug; 61(4):209-40. PubMed ID: 19024644 [TBL] [Abstract][Full Text] [Related]
6. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2002)]. Shimada K; Nakano K; Igari J; Oguri T; Ikemoto H; Mori T; Yokouchi H; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Okada S; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Nakata K; Nakatani T; Inagawa H; Kudo K; Kobayashi N; Tanaka T; Kobayashi H; Goto H; Kawai S; Takeda H; Sumitomo M; Matsushima T; Niki Y; Kohno S; Miyazaki Y; Yanagihara K; Hirakata Y; Matsuda J; Nasu M; Hiramatsu K; Suga M; Tosaka M Jpn J Antibiot; 2004 Jun; 57(3):213-45. PubMed ID: 15376784 [TBL] [Abstract][Full Text] [Related]
7. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2003)]. Goto H; Takeda H; Kawai S; Nakadate T; Shimada K; Nakano K; Suwabe A; Yokouchi H; Okada S; Ashino Y; Ikemoto H; Gejyo F; Igari J; Okada M; Oguri T; Aoki N; Mori T; Yamamoto M; Kitamura N; Inoue H; Suzuki Y; Karasawa Y; Tosaka M; Kudo K; Kobayashi N; Kohno S; Tanaka T; Hirakata Y; Kondo A; Matsuda J; Nakano M; Sumitomo M; Nasu M; Niki Y; Hiramatsu K; Suga M; Suzuki Y Jpn J Antibiot; 2005 Jun; 58(3):326-58. PubMed ID: 16161758 [TBL] [Abstract][Full Text] [Related]
8. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2006)]. Goto H; Takeda H; Kawai S; Suwabe A; Watanabe S; Okazaki M; Ashino Y; Shimada K; Aoki N; Sato T; Honma Y; Mori T; Kudo K; Sugiyama H; Kondo S; Tanaka T; Kido K; Yoshimura K; Oguri T; Yamamoto M; Nakamori Y; Inoue H; Yamauchi K; Sumitomo M; Endo S; Nakadate T; Oka M; Kobashi Y; Saita N; Yanagihara K; Kondou A; Matsuda J; Nakano M; Kohno S; Oikawa S Jpn J Antibiot; 2013 Dec; 66(6):331-55. PubMed ID: 24649798 [TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563 [TBL] [Abstract][Full Text] [Related]
10. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Farrell DJ; Sader HS; Castanheira M; Biedenbach DJ; Rhomberg PR; Jones RN Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548 [TBL] [Abstract][Full Text] [Related]
11. Surveillance of the activity of solithromycin (CEM-101) against bacteria from respiratory tract infections. Hawser S; Morrissey I; Lemos B; Keedy K; Fernandes P Int J Antimicrob Agents; 2017 Jul; 50(1):17-22. PubMed ID: 28483717 [TBL] [Abstract][Full Text] [Related]
12. Activity of a novel series of acylides active against community-acquired respiratory pathogens. Pandya M; Chakrabarti A; Rathy S; Katoch R; Venkataraman R; Bhateja P; Mathur T; Kumar GR; Malhotra S; Rao M; Bhadauria T; Barman TK; Das B; Upadhyay D; Bhatnagar PK Int J Antimicrob Agents; 2010 Aug; 36(2):169-74. PubMed ID: 20493666 [TBL] [Abstract][Full Text] [Related]
13. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens. Noviello S; Ianniello F; Leone S; Esposito S J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672 [TBL] [Abstract][Full Text] [Related]
14. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Pfaller MA; Farrell DJ; Sader HS; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951 [TBL] [Abstract][Full Text] [Related]
15. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010]. Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953 [TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Thabit AK; Crandon JL; Nicolau DP Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics. Friedland I; Mixson LA; Majumdar A; Motyl M; Woods GL J Chemother; 2002 Oct; 14(5):483-91. PubMed ID: 12462428 [TBL] [Abstract][Full Text] [Related]
19. Eravacycline (TP-434) is efficacious in animal models of infection. Grossman TH; Murphy TM; Slee AM; Lofland D; Sutcliffe JA Antimicrob Agents Chemother; 2015 May; 59(5):2567-71. PubMed ID: 25691636 [TBL] [Abstract][Full Text] [Related]
20. Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Castanheira M; Gales AC; Pignatari AC; Jones RN; Sader HS Microb Drug Resist; 2006; 12(2):91-8. PubMed ID: 16922623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]